Saturday 17 October 2026 Export ZYME’s income statement to Excel — free account

Zymeworks Inc.

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.

25.07 0.68 −2.64%

Follow ZYME

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: 16.2×
Dividend yield: —
F-score: 7/9
Altman Z: 11.56
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 5.03

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	7	—	—	—	—	—	—	—	—	1

Insider Ownership 5.58%

Capital & Financial Ratios $m

Market Cap 1,840.00

Revenue 37.13

Net Income (149.99)

Free Cash Flow (120.54)

Net Debt (270.70)

Current Ratio 6.32

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 16.20

P/S ratio 49.29

P/B ratio 22.77

Past 5Y EPS Growth —

This Y EPS Growth 196.74%

Next Y EPS Growth (1.86%)

Next Y revenue growth 173.20%

Next 5Y EPS Growth 69.06%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 79.17%

10-year low 10-year high

P/B against its own 10 years 97.82%

10-year low 10-year high

EV/Sales against its own 10 years 83.37%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	374	226	229	271
Receivables	19	56	5	6
Inventory	—	—	—	—
Other	—	—	—	—
	413	300	249	298

	2023	2024	2025	Q'26
Payables	46	60	36	27
ST’ Debt	—	—	—	—
Other	—	—	—	—
	56	88	42	47

Compound Annual Growth %

	10y	5y	3y
Sales	27.06%	22.16%	(36.43%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	30.86%	(8.11%)	(18.33%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	5	—	—	—
’25	27	49	28	3	106
’24	10	19	16	31	76
’23	36	7	17	17	76
’22	2	5	3	402	412
’21	1	2	4	20	27
’20	8	12	3	16	39

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(46)	(32)	—	—	—
’25	(3)	12	(31)	(10)	(33)
’24	(38)	(25)	(6)	(42)	(110)
’23	(83)	(6)	(43)	14	(118)
’22	(55)	(55)	(73)	327	144
’21	(41)	(50)	(51)	(51)	(192)
’20	(37)	(50)	(16)	(48)	(151)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(46)	(32)	—	—	—
’25	(4)	11	(32)	(11)	(35)
’24	(38)	(26)	(7)	(42)	(113)
’23	(84)	(7)	(44)	12	(122)
’22	(60)	(59)	(77)	326	131
’21	(41)	(52)	(56)	(56)	(206)
’20	(38)	(52)	(19)	(49)	(158)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.59)	(0.62)	—	—	—
’25	(0.30)	0.03	(0.26)	(0.55)	(1.08)
’24	(0.42)	(0.49)	(0.39)	(0.31)	(1.62)
’23	(0.37)	(0.76)	(0.41)	(0.20)	(1.72)
’22	(1.19)	(0.97)	(0.72)	4.65	1.90
’21	(0.87)	(1.31)	(1.25)	(0.72)	(4.61)
’20	(0.64)	(0.77)	(1.43)	(0.74)	(3.58)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	6.25	7.69	13.96	20.33	14.90	4.11	6.02	7.97	9.03	Analyst estimates 2026–2028 Powerpack
	High	—	14.25	29.00	45.83	56.73	59.03	17.27	10.99	17.70	28.49
People
People	Employees	117	147	183	256	355	458	294	277	286	264
	Revenue/emp, $m	0.09	0.35	0.29	0.12	0.11	0.06	1.40	0.27	0.27	0.40
Income, $m
Income, $m	Revenue	11	52	53	30	39	27	412	76	76	106
	Gross margin, %	(234.42)	19.34	(7.37)	(292.30)	(339.53)	(648.70)	49.43	(88.94)	(76.43)	(29.29)
	EBT	(39)	(10)	(34)	(146)	(180)	(212)	135	(119)	(117)	(80)
	EBT margin, %	(353.20)	(19.25)	(64.85)	(494.24)	(462.43)	(795.95)	32.79	(156.87)	(152.82)	(75.26)
	Net income	(34)	(10)	(37)	(145)	(181)	(212)	124	(119)	(123)	(81)
	Depreciation	1	3	4	7	10	10	7	17	11	11
Per share, $
Per share, $	Revenue	0.86	2.44	1.82	0.78	0.77	0.52	6.33	1.10	1.01	1.41
	Earnings	(2.65)	(0.51)	(1.26)	(3.83)	(3.58)	(4.11)	1.91	(1.72)	(1.62)	(1.08)
	Cash flow	(2.77)	0.01	0.83	(2.15)	(3.01)	(3.73)	2.21	(1.72)	(1.45)	(0.44)
	Capex	(0.43)	(0.15)	(0.12)	(0.36)	(0.12)	(0.26)	(0.20)	(0.06)	(0.04)	(0.03)
	Free cash flow	(3.20)	(0.14)	0.71	(2.52)	(3.13)	(3.99)	2.01	(1.78)	(1.49)	(0.47)
	Book value	5.33	5.48	6.20	6.46	8.14	4.83	7.56	6.75	4.47	3.56
	Shares, m	13	21	29	38	50	52	65	69	76	75
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	4.24	0.00	0.00	0.00
	P/S	15.62	3.26	8.05	58.51	61.13	31.67	1.19	9.40	14.55	18.74
	P/B	0.00	1.45	2.37	7.04	5.81	3.39	1.00	1.54	3.28	7.39
	EV/Sales	13.59	1.65	4.36	48.58	50.34	23.37	0.06	4.78	11.89	16.58
	EV/FCF	(3.16)	(29.37)	11.15	(14.61)	(12.44)	(3.03)	0.18	(2.89)	(8.02)	(49.69)
Cash, $m
Cash, $m	Operating cash flow	(35)	0	24	(82)	(151)	(192)	144	(118)	(110)	(33)
	Capex	(5)	(3)	(3)	(14)	(6)	(13)	(13)	(4)	(3)	(2)
	Free cash flow	(41)	(3)	21	(96)	(158)	(206)	131	(122)	(113)	(35)
Balance, $m
Balance, $m	Working capital	30	78	174	229	369	216	449	357	212	206
	Total debt	4	0	0	6	6	31	25	—	—	—
	Net debt	(36)	(88)	(200)	(299)	(426)	(253)	(492)	(374)	(226)	(229)
	Shareholders’ equity	68	116	180	246	410	249	493	465	339	269
Returns, %
Returns, %	ROA	(57.72)	(9.67)	(19.42)	(47.48)	(39.83)	(45.68)	23.96	(19.30)	(23.51)	(20.04)
	ROIC	(73.91)	(19.64)	0.00	0.00	0.00	0.00	11,267.96	(95.36)	(75.84)	(145.69)
	ROE	(248.22)	(17.42)	(24.62)	(68.25)	(55.08)	(64.29)	33.51	(24.78)	(30.54)	(26.72)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MLYS Mineralys Therapeutics, Inc.	$1.9B	— (loss-making)	—	—	n/m	−7.91% (below 0%: shrinking)	—	0.00%	Compare
SRPT Sarepta Therapeutics, Inc.	$1.9B	— (loss-making)	4.4×	−34.34% (below 0%: shrinking)	n/m	−14.48% (below 0%: shrinking)	62.77%	3.31%	Compare
ZYME Zymeworks Inc.	$1.8B	— (loss-making)	16.2×	−90.58% (below 0%: shrinking)	n/m	−385.53% (below 0%: shrinking)	(497.71%)	(918.95%)
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+8.53% (above 0%: growing)	n/m	+127.57% (above 0%: growing)	40.14%	(29.33%)	Compare
PVLA Palvella Therapeutics, Inc.	$1.8B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
MESO Mesoblast Limited	$1.8B	— (loss-making)	—	−13.41% (below 0%: shrinking)	n/m	−89.23% (below 0%: shrinking)	(353.35%)	(909.40%)	Compare
URGN Urogen Pharma	$1.8B	— (loss-making)	— (loss-making)	+199.22% (above 0%: growing)	n/m	+17.26% (above 0%: growing)	90.93%	0.15%	Compare
XNCR Xencor, Inc.	$1.8B	— (loss-making)	— (loss-making)	+17.46% (above 0%: growing)	n/m	−52.91% (below 0%: shrinking)	100.00%	(72.37%)	Compare
VIR Vir Biotechnology, Inc.	$1.8B	— (loss-making)	— (loss-making)	+19,582.54% (above 0%: growing)	n/m	+200.47% (above 0%: growing)	100.00%	30.75%	Compare
Median of peers	$1.8B	—	—	+8.53%	—	−11.20%	90.93%	0.00%

All 614 Biotechnology stocks →

Zymeworks Inc. (ZYME) key facts

Strength: Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
Zymeworks Inc. (ZYME) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ZYME traded at $25.07, a market capitalization of $1.8 billion.
Return on equity was −26.7% and debt-to-equity 0.00.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 11.56 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.